Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Alizyme |
---|---|
Information provided by: | Alizyme |
ClinicalTrials.gov Identifier: | NCT00607971 |
The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).
Condition | Intervention | Phase |
---|---|---|
Constipation-Predominant Irritable Bowel Syndrome |
Drug: Renzapride |
Phase III |
Study Type: | Interventional |
Study Design: | Open Label, Single Group Assignment, Safety Study |
Official Title: | A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C) |
Enrollment: | 939 |
Study Start Date: | April 2006 |
Study Completion Date: | June 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
|
Drug: Renzapride
All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
|
Since IBS is a chronic condition affecting patients over many years, it is anticipated that renzapride will be prescribed and used by patients on a daily basis for long periods of time. Hence the need to understand its long-term safety and tolerability in the target population. This study is open label and so all subjects will take renzapride and will know that they are taking it. Enrolment in to this study is restricted to subjects completing a 12-week, placebo-controlled study of the effectiveness of renzapride in providing relief from IBS-C (Study no. ATL1251/038/CL).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Anthony Lembo, MD | Beth Israel Deaconess Medical Center, Boston |
Responsible Party: | Alizyme Therapeutics Ltd ( Research & Development Director ) |
Study ID Numbers: | ATL1251/052/CL |
Study First Received: | January 23, 2008 |
Last Updated: | July 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00607971 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Constipation predominant irritable bowel syndrome |
Renzapride Signs and Symptoms Neurotransmitter Agents Digestive System Diseases Signs and Symptoms, Digestive Gastrointestinal Diseases |
Colonic Diseases Irritable Bowel Syndrome Constipation Intestinal Diseases Colonic Diseases, Functional Serotonin |
Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Signs and Symptoms, Digestive Gastrointestinal Diseases Physiological Effects of Drugs Colonic Diseases Intestinal Diseases Pharmacologic Actions Signs and Symptoms |
Renzapride Serotonin Antagonists Serotonin Agents Digestive System Diseases Pathologic Processes Syndrome Irritable Bowel Syndrome Constipation Colonic Diseases, Functional |